{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:19:34Z","timestamp":1783664374102,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006070","name":"Society of Surgical Oncology","doi-asserted-by":"publisher","award":["Young Investigator Award (2019)"],"award-info":[{"award-number":["Young Investigator Award (2019)"]}],"id":[{"id":"10.13039\/100006070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08 CA237726-01A1"],"award-info":[{"award-number":["K08 CA237726-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-CA093245"],"award-info":[{"award-number":["T32-CA093245"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1245\/s10434-020-09277-w","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T18:03:30Z","timestamp":1605636210000},"page":"3501-3510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma"],"prefix":"10.1245","volume":"28","author":[{"given":"Norma E.","family":"Farrow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eda K.","family":"Holl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin-Ho","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami N.","family":"Al-Rohil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Selim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Ollila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Antonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S.","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita K.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia M.","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"9277_CR1","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1245\/s10434-019-07369-w","volume":"26","author":"DC Thomas","year":"2019","unstructured":"Thomas DC, Han G, Leong SP, et al. Recurrence of melanoma after a negative sentinel node biopsy: predictors and impact of recurrence site on survival. Ann Surg Oncol. 2019;26:2254\u201362.","journal-title":"Ann Surg Oncol."},{"key":"9277_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jaad.2016.10.018","volume":"76","author":"SM Landow","year":"2017","unstructured":"Landow SM, Gjelsvik A, Weinstock MA. Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992\u20132013. J Am Acad Dermatol. 2017;76:258\u201363.","journal-title":"J Am Acad Dermatol."},{"issue":"86","key":"9277_CR3","first-page":"101","volume":"2017","author":"AMM Eggermont","year":"1990","unstructured":"Eggermont AMM, Dummer R. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients. Eur J Cancer Oxford Engl 1990. 2017;86:101\u20135.","journal-title":"Eur J Cancer Oxford Engl"},{"key":"9277_CR4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789\u2013801.","journal-title":"N Engl J Med."},{"key":"9277_CR5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824\u201335.","journal-title":"N Engl J Med."},{"key":"9277_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.18553\/jmcp.2017.23.6.653","volume":"23","author":"A Oh","year":"2017","unstructured":"Oh A, Tran DM, McDowell LC, et al. Cost-effectiveness of nivolumab-ipilimumab combination therapy compared with monotherapy for first-line treatment of metastatic melanoma in the United States. J Manag Care Specialty Pharm. 2017;23:653\u201364.","journal-title":"J Manag Care Specialty Pharm."},{"key":"9277_CR7","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845\u201355.","journal-title":"N Engl J Med."},{"key":"9277_CR8","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813\u201323.","journal-title":"N Engl J Med."},{"key":"9277_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","volume":"17","author":"DG Coit","year":"2019","unstructured":"Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma, version 2.2019 NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:367\u2013402.","journal-title":"J Natl Compr Canc Netw."},{"key":"9277_CR10","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1200\/JCO.2009.27.1627","volume":"28","author":"CM Balch","year":"2010","unstructured":"Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452\u20139.","journal-title":"J Clin Oncol."},{"key":"9277_CR11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472\u201392.","journal-title":"CA Cancer J Clin."},{"key":"9277_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nri1919","volume":"6","author":"AJ Cochran","year":"2006","unstructured":"Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol. 2006;6:659\u201370.","journal-title":"Nat Rev Immunol."},{"key":"9277_CR13","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/2326-6066.CIR-14-0167","volume":"3","author":"A Holtzhausen","year":"2015","unstructured":"Holtzhausen A, Zhao F, Evans KS, et al. Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: opportunities for pharmacologic enhancement of immunotherapy. Cancer Immunol Res. 2015;3:1082\u201395.","journal-title":"Cancer Immunol Res."},{"key":"9277_CR14","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1158\/2326-6066.CIR-17-0110","volume":"5","author":"M van den Hout","year":"2017","unstructured":"van den Hout M, Koster BD, Sluijter BJR, et al. Melanoma sequentially suppresses different DC subsets in the sentinel lymph node, affecting disease spread and recurrence. Cancer Immunol Res. 2017;5:969\u201377.","journal-title":"Cancer Immunol Res."},{"key":"9277_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/14737159.2017.1268533","volume":"17","author":"HF Tsang","year":"2017","unstructured":"Tsang HF, Xue VW, Koh SP, Chiu YM, Ng LP, Wong SC. NanoString, a novel digital color-coded barcode technology: current and future applications in molecular diagnostics. Expert Rev Mol Diagnostics. 2017;17:95\u2013103.","journal-title":"Expert Rev Mol Diagnostics."},{"key":"9277_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nbt1385","volume":"26","author":"GK Geiss","year":"2008","unstructured":"Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26:317\u201325.","journal-title":"Nat Biotechnol."},{"key":"9277_CR17","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/S0140-6736(05)67482-X","volume":"366","author":"AM Eggermont","year":"2005","unstructured":"Eggermont AM, Suciu S, MacKie R, et al. Postsurgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb\/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005;366:1189\u201396.","journal-title":"Lancet."},{"key":"9277_CR18","first-page":"CD008955","volume":"6","author":"S Mocellin","year":"2013","unstructured":"Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev. 2013(6):CD008955.","journal-title":"Cochrane Database Syst Rev."},{"key":"9277_CR19","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/cncr.23251","volume":"112","author":"A Hauschild","year":"2008","unstructured":"Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer. 2008;112:982\u201394.","journal-title":"Cancer."},{"key":"9277_CR20","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1245\/s10434-018-6647-7","volume":"25","author":"AJ Sinnamon","year":"2018","unstructured":"Sinnamon AJ, Song Y, Sharon CE, et al. Prediction of residual nodal disease at completion dissection following positive sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2018;25:3469\u201375.","journal-title":"Ann Surg Oncol."},{"key":"9277_CR21","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.2217\/fon-2019-0666","volume":"16","author":"JJ Luke","year":"2020","unstructured":"Luke JJ, Ascierto PA, Carlino MS, et al. KEYNOTE-716: phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020;16:4429\u201338.","journal-title":"Future Oncol."},{"key":"9277_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12885-018-4016-3","volume":"18","author":"JS Zager","year":"2018","unstructured":"Zager JS, Gastman BR, Leachman S, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer. 2018;18:130.","journal-title":"BMC Cancer."},{"key":"9277_CR23","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1002\/cam4.2128","volume":"8","author":"J Keller","year":"2019","unstructured":"Keller J, Schwartz TL, Lizalek JM, et al. Prospective validation of the prognostic 31-gene expression-profiling test in primary cutaneous melanoma. Cancer Med. 2019;8:2205\u201312.","journal-title":"Cancer Med."},{"issue":"125","key":"9277_CR24","first-page":"38","volume":"2020","author":"TMS Amaral","year":"1990","unstructured":"Amaral TMS, Hoffmann MC, Sinnberg T, et al. Clinical validation of a prognostic 11-gene expression-profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. Eur J Cancer Oxford, Engl 1990. 2020;125:38\u201345.","journal-title":"Eur J Cancer Oxford, Engl"},{"key":"9277_CR25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/415530a","volume":"415","author":"LJ van \u2018t Veer","year":"2002","unstructured":"van \u2018t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression-profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530\u20136.","journal-title":"Nature."},{"key":"9277_CR26","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817\u201326.","journal-title":"N Engl J Med."},{"key":"9277_CR27","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1158\/0008-5472.CAN-15-0262","volume":"75","author":"MH Veldman-Jones","year":"2015","unstructured":"Veldman-Jones MH, Brant R, Rooney C, et al. Evaluating robustness and sensitivity of the NanoString Technologies nCounter Platform to enable multiplexed gene expression-analysis of clinical samples. Cancer Res. 2015;75:2587\u201393.","journal-title":"Cancer Res."},{"key":"9277_CR28","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/CMR.0000000000000383","volume":"27","author":"AA Tarhini","year":"2017","unstructured":"Tarhini AA, Floros T, Lin HM, et al. A unique gene-expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma. Melanoma Res. 2017;27:429\u201338.","journal-title":"Melanoma Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09277-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-020-09277-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-020-09277-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T13:20:25Z","timestamp":1623072025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-020-09277-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["9277"],"URL":"https:\/\/doi.org\/10.1245\/s10434-020-09277-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,17]]},"assertion":[{"value":"7 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no conflicts on interested related to this work. Dr. Beasley was a one-time consultant for Regneron in 2019.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}